COZADD BRUCE C sold $1.5M of JAZZ
COZADD BRUCE C sold 6,000 shares of Jazz Pharmaceuticals plc (JAZZ) at $252.98 ($1.52M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed event is an open-market sale by a director, with the company stating the sale was under a pre-arranged Rule 10b5-1 plan.
Market read
Traders may note the insider sale as a minor sentiment input, but the 10b5-1 structure limits interpretability as a new fundamental signal.
What to watch
The article does not provide context on total insider holdings changes over time, nor any concurrent operational or clinical catalysts for Jazz.
Background
The article is an SEC Form 4 insider transaction disclosure for Jazz Pharmaceuticals plc.
Ticker impact
Jazz Pharmaceuticals director COZADD BRUCE C sold 6,000 shares in an open-market transaction for about $1.52M under a 10b5-1 plan.
Likely limited near-term impact; any effect would be short-lived unless accompanied by other company-specific news.
The filing is a Form 4 insider transaction with a stated 10b5-1 plan, which typically reduces the signal strength versus discretionary selling.
Market effects
No clear sector read-through from a single 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerJazz Pharmaceuticals plc
Subject of the Form 4 insider transaction disclosure.
- insiderCOZADD BRUCE C
Director who sold 6,000 shares on 2026-08-03.
